e/HspE7

Information
has gloss	eng: HspE7 is an investigational therapeutic vaccine candidate being developed by Nventa Biopharmaceuticals for the treatment of precancerous and cancerous lesions caused by the human papillomavirus (HPV). HspE7 uses recombinant DNA technology to covalently fuse a heat shock protein (Hsp) to a target antigen, thereby stimulating cellular immune system responses to specific diseases. HspE7 is a patented construct consisting of the HPV Type 16 E7 protein and heat shock protein 65 (Hsp65) and is currently the only candidate using Hsp technology to target the over 20 million Americans already infected with HPV.
lexicalization	eng: HspE7
instance of	(noun) immunogen consisting of a suspension of weakened or dead pathogenic cells injected in order to stimulate the production of antibodies vaccinum, vaccine

Media
media:img	HspE7 Construct.gif